Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 218

1.

No Differences in Population-Based Readmissions After Open and Robotic-Assisted Cystectomy: Implications for Post-Discharge Care.

Borza T, Jacobs BL, Montgomery JS, Weizer AZ, Morgan TM, Hafez KS, Lee CT, Y B Li, Min HS, He C, Gilbert SM, Helm JE, Lavieri MS, Hollenbeck BK, A Skolarus T.

Urology. 2017 Mar 3. pii: S0090-4295(17)30229-7. doi: 10.1016/j.urology.2017.01.042. [Epub ahead of print]

PMID:
28267606
2.

Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease.

Kirk PS, Govani S, Borza T, Hollenbeck BK, Davis J, Shumway D, Waljee AK, Skolarus TA.

Urology. 2017 Feb 3. pii: S0090-4295(17)30111-5. doi: 10.1016/j.urology.2017.01.030. [Epub ahead of print]

PMID:
28163082
3.

Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.

Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE.

BJU Int. 2017 Jan 31. doi: 10.1111/bju.13792. [Epub ahead of print]

PMID:
28139024
4.

Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men.

Borza T, Kaufman SR, Shahinian VB, Yan P, Miller DC, Skolarus TA, Hollenbeck BK.

Health Aff (Millwood). 2017 Jan 1;36(1):108-115. doi: 10.1377/hlthaff.2016.0739.

PMID:
28069853
5.

Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population.

Osawa T, Ambani SN, Olugbade K Jr, Skolarus TA, Weizer AZ, Montgomery JS, He C, Hafez KS, Hollenbeck BK, Lee CT, Montie JE, Palapattu GS, Morgan TM.

Urology. 2016 Dec 21. pii: S0090-4295(16)30925-6. doi: 10.1016/j.urology.2016.10.051. [Epub ahead of print]

PMID:
28013038
6.

Variation in the Use of Open Pyeloplasty, Minimally Invasive Pyeloplasty, and Endopyelotomy for the Treatment of Ureteropelvic Junction Obstruction in Adults.

Jacobs BL, Lai JC, Seelam R, Hanley JM, Wolf JS Jr, Hollenbeck BK, Hollingsworth JM, Dick AW, Setodji CM, Saigal CS.

J Endourol. 2017 Feb;31(2):210-215. doi: 10.1089/end.2016.0688. Epub 2017 Jan 5.

PMID:
27936909
7.

Cost Analysis of Treatments for Ureteropelvic Junction Obstruction.

Jacobs BL, Seelam R, Lai JC, Hanley JM, Wolf JS Jr, Hollenbeck BK, Hollingsworth JM, Dick AW, Setodji CM, Saigal CS.

J Endourol. 2017 Feb;31(2):204-209. doi: 10.1089/end.2016.0722. Epub 2017 Jan 5.

PMID:
27927021
8.

Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data.

Smaldone MC, Egleston B, Hollingsworth JM, Hollenbeck BK, Miller DC, Morgan TM, Kim SP, Malhotra A, Handorf E, Wong YN, Uzzo RG, Kutikov A.

Med Care. 2017 Apr;55(4):398-404. doi: 10.1097/MLR.0000000000000657.

PMID:
27820596
9.

Independent surgical validation of the new prostate cancer grade-grouping system.

Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM.

BJU Int. 2016 Nov;118(5):763-769. doi: 10.1111/bju.13488. Epub 2016 Apr 19.

PMID:
27009882
10.

Health Care Integration and Quality among Men with Prostate Cancer.

Herrel LA, Kaufman SR, Yan P, Miller DC, Schroeck FR, Skolarus TA, Shahinian VB, Hollenbeck BK.

J Urol. 2017 Jan;197(1):55-60. doi: 10.1016/j.juro.2016.07.040. Epub 2016 Jul 15.

PMID:
27423758
11.

Implications of evolving delivery system reforms for prostate cancer care.

Hollenbeck BK, Bierlein MJ, Kaufman SR, Herrel L, Skolarus TA, Miller DC, Shahinian VB.

Am J Manag Care. 2016 Sep;22(9):569-75.

12.

A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy.

Osawa T, Lee CT, Abe T, Takada N, Hafez KS, Montgomery JS, Weizer AZ, Hollenbeck BK, Skolarus TA, Murai S, Shinohara N, Morgan TM.

Bladder Cancer. 2016 Apr 27;2(2):251-261.

13.

Using Analytic Morphomics to Understand Short-Term Convalescence after Radical Cystectomy.

Luckenbaugh AN, Hollenbeck BK, Montgomery JS, Lee CT, Gilbert SM, Dunn RL, Friedman JF, Englesbe MJ, Wang SC, Hollingsworth JM.

Bladder Cancer. 2016 Apr 27;2(2):235-240.

14.

Patient-Reported Convalescence and Quality of Life Recovery: A Comparison of Open and Robotic-Assisted Radical Cystectomy.

Li AY, Filson CP, Hollingsworth JM, He C, Weizer AZ, Hollenbeck BK, Gilbert SM, Hafez KS, Lee CT, Dunn RL, Montgomery JS.

Surg Innov. 2016 Dec;23(6):598-605. Epub 2016 Jun 28.

PMID:
27354552
15.

Early impact of Medicare accountable care organizations on cancer surgery outcomes.

Herrel LA, Norton EC, Hawken SR, Ye Z, Hollenbeck BK, Miller DC.

Cancer. 2016 Sep 1;122(17):2739-46. doi: 10.1002/cncr.30111. Epub 2016 May 24.

PMID:
27218198
16.

Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy.

Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM.

Urol Oncol. 2016 Sep;34(9):415.e1-6. doi: 10.1016/j.urolonc.2016.03.019. Epub 2016 Apr 29.

PMID:
27140065
17.

Factors Associated With Preventive Pharmacological Therapy Adherence Among Patients With Kidney Stones.

Dauw CA, Yi Y, Bierlein MJ, Yan P, Alruwaily AF, Ghani KR, Wolf JS Jr, Hollenbeck BK, Hollingsworth JM.

Urology. 2016 Jul;93:45-9. doi: 10.1016/j.urology.2016.03.030. Epub 2016 Mar 31.

PMID:
27041472
18.

Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.

Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R.

J Urol. 2016 Aug;196(2):405-11. doi: 10.1016/j.juro.2016.01.120. Epub 2016 Feb 23.

PMID:
26920466
19.

Urologist Participation in Medicare Shared Savings Program Accountable Care Organizations (ACOs).

Hawken SR, Herrel LA, Ellimoottil C, Ye Z, Hollenbeck BK, Miller DC.

Urology. 2016 Apr;90:76-80. doi: 10.1016/j.urology.2015.12.053. Epub 2016 Jan 22.

PMID:
26809069
20.

A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy.

Krishnan N, Liu X, Lavieri MS, Hu M, Helfand A, Li B, Helm JE, He C, Hollenbeck BK, Skolarus TA, Jacobs BL.

J Urol. 2016 May;195(5):1362-7. doi: 10.1016/j.juro.2015.11.063. Epub 2015 Dec 10.

PMID:
26682758

Supplemental Content

Loading ...
Support Center